Alzheimer's Vaccine Shows Promise in Mice
MONDAY, Nov. 26, 2018 -- An experimental Alzheimer's disease vaccine shows promise in animal tests, and researchers say it could have the potential to reduce dementia cases by half.
In mice created to develop Alzheimer's, the vaccine triggered an immune response that reduced accumulation of two toxic proteins associated with the fatal brain disease.
There was a 40 percent reduction in beta-amyloid proteins and up to a 50 percent reduction in tau proteins, with no harmful side effects, according to researchers at the University of Texas.
But there's a catch: While such tests showed positive results in mice, research on animals doesn't always produce the same effects in humans. More study is needed.
Still, the researchers remained optimistic. Reductions in these proteins could someday have significant benefits in people at risk for Alzheimer's disease, said study senior author Doris Lambracht-Washington, of the UT Southwestern Medical Center Brain Institute in Dallas.
"If the onset of the disease could be delayed by even five years, that would be enormous for the patients and their families," she said in a center news release. "The number of dementia cases could drop by half."
Lead researcher Dr. Roger Rosenberg is founding director of the Alzheimer's Disease Center at UT Southwestern.
"This study is the culmination of a decade of research that has repeatedly demonstrated that this vaccine can effectively and safely target in animal models what we think may cause Alzheimer's disease," said Rosenberg.
"I believe we're getting close to testing this therapy in people," he added.
Two previous studies from Rosenberg's lab showed that the vaccine triggered similar immune responses in rabbits and monkeys.
UT Southwestern scientists are also working to create a test to detect abnormal tau levels in spinal fluid before the memory-loss symptoms of Alzheimer's appear. They said such a test would identify people who could benefit from the vaccine.
In people with Alzheimer's, the beta-amyloid and tau proteins spread in lethal plaques and tangles on the brain, the study authors explained.
"The longer you wait [to administer the vaccine], the less effect it will probably have," Rosenberg said. "Once those plaques and tangles have formed, it may be too late."
About 5.7 million Americans have Alzheimer's disease. That number is expected to more than double by the year 2050, according to the U.S. Centers for Disease Control and Prevention. There is no effective treatment for the disease.
The study was published recently in the journal Alzheimer's Research and Therapy.
© 2020 HealthDay. All rights reserved.
Posted: November 2018
Read this next
WEDNESDAY, Oct. 21, 2020 -- Dr. Anthony Fauci, the leading infectious disease expert in the United States, said on Wednesday he is "cautiously optimistic" that a COVID-19 vaccine...
TUESDAY, Oct. 20, 2020 -- As the air people breathe gets dirtier, their odds for serious neurological disorders such as Parkinson's disease, Alzheimer's and other dementias rises,...
TUESDAY, Oct. 20, 2020 -- Promoting any emerging COVID-19 vaccine to a skeptical public could be tough. But a new survey finds vaccine uptake might rise if the shot is promoted...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.